MSPOLMIN Sustained Release Tablets 5/50/750 mg (Empagliflozin, Sitagliptin, Metformin)
Metformin Hydrochloride 750mg · Sitagliptin Phosphate Hydrate 64.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
MFDS item code 202500916 · Approved 2025.04.16
Improves blood glucose control in adults with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes improve blood glucose control. It is particularly suitable for adult patients who combine diet and exercise therapy, effectively managing blood glucose levels through a combination of three ingredients: empagliflozin, sitagliptin, and metformin. This supports stable maintenance of blood glucose levels and diabetes management.
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains sitagliptin, empagliflozin, and metformin. Firstly, the sitagliptin component can rarely cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking the medication, it should be discontinued immediately, and a doctor should be consulted. Moreover, sitagliptin can lead to acute pancreatitis, a serious side effect characterized by inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or nausea occur, the patient should go to the hospital immediately. The metformin component can rarely cause lactic acidosis, a very dangerous condition, so if symptoms such as shortness of breath, muscle pain, fatigue, abdominal pain, or vomiting occur, the medication should be stopped immediately and emergency treatment sought. This medication should not be used in patients with type 1 diabetes, severely impaired kidney function, severe liver disease, acute heart failure, or serious infections or dehydration. Especially before and after tests using radiocontrast agents, this medication should be temporarily discontinued, and it should be resumed only after confirming normal kidney function post-examination. Elderly patients or those with slightly impaired kidney function should undergo regular kidney function tests, and dosage adjustment or discontinuation may be considered if necessary. This medication has glucose-lowering effects, so caution is needed when taken with insulin or other glucose-lowering agents, as hypoglycemic symptoms may occur. Additionally, this medication can increase the risk of genital infections and urinary tract infections, so prompt treatment should be sought if symptoms of infection arise. Symptoms of low blood pressure and dehydration can also occur due to fluid loss, so caution should be exercised to avoid dehydration from diarrhea or vomiting. If sudden joint pain or blistering skin conditions occur during medication use, a doctor should be informed immediately, and the medication may need to be discontinued if necessary. It is safe not to use this medication during pregnancy or in cases of severe liver dysfunction. While taking this medication, regular blood tests and physical examinations should be performed to monitor for adverse reactions, and if any abnormal symptoms occur, immediate consultation with medical personnel is recommended.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it is best to keep it at room temperature between 1°C and 30°C, avoiding extremely hot or cold conditions.
Purple, oval, double convex, sustained-release film-coated tablets
30 tablets/bottle, 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Metformin Hydrochloride 750mg · Sitagliptin Phosphate Hydrate 64.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 750mg · Sitagliptin Phosphate Hydrate 64.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Metformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.